These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9519357)
1. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Boccon-Gibod L Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357 [TBL] [Abstract][Full Text] [Related]
2. Antiandrogen monotherapy in the management of advanced prostate cancer. Kaisary AV Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906 [TBL] [Abstract][Full Text] [Related]
3. Nilutamide: an antiandrogen for the treatment of prostate cancer. Dole EJ; Holdsworth MT Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470 [TBL] [Abstract][Full Text] [Related]
4. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Sciarra A; Cardi A; Di Silverio F Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347 [TBL] [Abstract][Full Text] [Related]
5. The role of antiandrogen monotherapy in the treatment of prostate cancer. Anderson J BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397 [TBL] [Abstract][Full Text] [Related]
6. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Kolvenbag GJ; Iversen P; Newling DW Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439 [TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Mahler C; Verhelst J; Denis L Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622 [TBL] [Abstract][Full Text] [Related]
9. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy. Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793 [TBL] [Abstract][Full Text] [Related]
10. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen. Sarosdy MF Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288 [TBL] [Abstract][Full Text] [Related]
11. [The role of bicalutamide in the treatment of prostate cancer]. Stav SY; Segal G Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896 [TBL] [Abstract][Full Text] [Related]
12. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Kolvenbag GJ; Blackledge GR; Gotting-Smith K Prostate; 1998 Jan; 34(1):61-72. PubMed ID: 9428389 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. Davis NB; Ryan CW; Stadler WM; Vogelzang NJ BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201 [TBL] [Abstract][Full Text] [Related]
16. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Schröder FH Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460 [TBL] [Abstract][Full Text] [Related]
17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
18. Clinical progress with a new antiandrogen, Casodex (bicalutamide). Blackledge GR Eur Urol; 1996; 29 Suppl 2():96-104. PubMed ID: 8717470 [TBL] [Abstract][Full Text] [Related]